DOI: https://dx.doi.org/10.18203/2349-2902.isj20222956
Published: 2022-10-29

Appendicular mass with pseudomyxoma peritonei: a case report

Brahampreet S. Kang, Anshika Arora, Meena Harsh

Abstract


Pseudomyxoma peritonei is an infrequently occurring clinical entity having an annual incidence of less than two per million. It is originated from the rupture of a tumour filled with mucinous substance. The intra-abdominal viscera are usually covered with a jelly-like substance. This syndrome originates most frequently from tumours of the appendix or ovaries. Genetic history is expected to play a role in the appendicular mucocele. The disease advances due to the presence of microbial agents expressed in carcinomas associated with gelatinous ascites. It typically has an insidious onset with a non-exclusive presentation like an increase in abdominal girth and associated abdominal pain with locoregional dissemination initially and dissemination to multiple sites later. The main sign is pelvic ascites. Diagnosis is made by combining radiological imaging with histopathology. Ultrasound aids in identifying the pelvic mass, peritoneal implants, calcifications, effusion, septa, the associated tumours (e.g., ovaries), the involvement of mesentery, and finalizing the surgical strategy. Usually, this condition is adequately treated by combining surgical excision and/or hyperthermic intra-peritoneal chemotherapy (HIPEC), which may be omitted by selecting the patient carefully.


Keywords


Appendicular mass, Pseudomyxoma peritonei, Mucinous cyst

Full Text:

PDF

References


Smeenk RM, van Velthuysen ML, Verwaal VJ, Zoetmulder FA. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol. 2008;34:196-201.

Mittal R, Chandramohan A, Moran B. Pseudomyxoma peritonei: natural history and treatment. Int J Hyperthermia. 2017;33(5):511-9.

Smeenk RM, van Velthuysen ML, Verwaal VJ, Zoetmulder FA. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol. 2008;34:196-201.

Jivan S, Bahal V. Pseudomyxoma peritonei. Postgrad Med J 2002;78:170-2..

Wrafter PF, Connelly T, Khan JS, Joyce WP. Pseudomyxoma peritonei diagnosed 19 years after appendicectomy. BMJ Case Rep. 2015;bcr2015211706.

Semino-Mora C, Liu H, Macavoy T, Nieroda C, Studeman K, Sardi A, et al. Pseudomyxoma peritonei: is disease progression related to microbial agents? A study of bacteria, MUC2 and MUC5AC expression in disseminated peritonel adenomucinosis and peritoneal mucinous carcinomatosis. Ann Surg Oncol. 2008;15(5):1414-23.

O’Connell JT, Hacker CM, Barsky SH. MUC2 is a molecular marker for pseudomyxoma peritonei. Mod Pathol. 2002;15:958-72.

Derelle AL, Tissier S, Granger P, Barbary C, Rousseau A, Laurent V, et al. Diagnostic précoce de pseudomyxome péritonéal localisé à la zone de rupture d’une mucocèle appendiculaire: imagerie et aspects anatomopathologiques. J Radiol. 2007;88:289-95.

Zeraidi N, Chahtane A, Lakhdar A, Khabouz S, Berrada R, Rhrab B, et al. La maladie gélatineuse du péritoine à propos d’un cas. Médecine du Maghreb. 1996;59:34-6.

Fairise A, Barbary C, Derelle AL, Tissier S, Granger P, Marchal F, et al. Mucocele of the appendix and pseudomyxoma peritonei. Journal De Radiologie. 2008;89:751-62.

Buell-Gutbrod R, Gwin K. Pathologic diagnosis, origin, and natural history of pseudomyxoma peritonei. Am Soc Clin Oncol Educ Book. 2013:221-5.

Pugin F, Bouquet De Jolinière J, Major A, Khomsi F, Guillou L, Peter M, Ben Ali N, Egger B, Feki A. Pseudomyxoma Peritonei: A Case Report Diagnosed in a 47-Year-Old Woman with Chronic Pelvic Abdominal Pain and Appendicular Origin: Review of the Literature and Management. Front Surg. 2017;4:41.

Sulkin TV, O'Neill H, Amin AI, Moran B. CT in pseudomyxoma peritonei: a review of 17 cases. Clin Radiol. 2002;57(7):608-13.

Sio TT, Mansfield AS, Grotz TE, Graham RP, Molina JR, Que FG, Miller RC. Concurrent MCL1 and JUN amplification in pseudomyxoma peritonei: a comprehensive genetic profiling and survival analysis. J Hum Genet. 2014;59(3):124-8.

Dartigues P, Isaac S, Villeneuve L, Glehen O, Capovilla M, Chevallier A, Croce S, Kaci R, Lang-Averous G, Laverriere MH, Leroux-Broussier A, Mery É, Poizat F, Valmary-Degano S, Verriele-Beurrier V, Gilly FN, Bibeau F Ann Pathol. 2014;34(1):14-25.

Hubner M, Teixeira H, Boussaha T, Cachemaille M, Lehmann K, Demartines N. PIPAC-Chimiothérapie intrapéritonéale vaporisée. Un traitement innovateur de la carcinose péritonéale. Rev Med Suisse. 2015;11:1325-30.

Wrafter PF, Connelly T, Khan JS, Joyce WP. Pseudomyxoma peritonei diagnosed 19 years after appendicectomy. BMJ Case Rep. 2015;bcr2015211706.

Buell-Gutbrod R, Gwin K. Pathologic diagnosis, origin, and natural history of pseudomyxoma peritonei. Am Soc Clin Oncol Educ Book. 2013:221-5.

Solaas W, Giger-Pabst U, Zieren J, Reymond MA. Pressurized intrapéritoneal aerosol chemotherapy (PIPAC): occupational health and safety aspects. Surg Oncol (2013) 20:3504–11.10.1245/s10434-013-3039-x

Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30(20):2449-56.

Wheeler BR, Reddy SK, Kenwright D, Keating JP. Treating pseudomyxoma peritonei without heated intraperitoneal chemotherapy--a first look in New Zealand. N Z Med J. 2014;127(1389):31-9.

Youssef H, Newman C, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ. Operative findings, early complications, and long-term survival in 456 patients with pseudomyxoma peritonei syndrome of appendiceal origin. Dis Colon Rectum. 2011;54(3):293-9.

McBride K, McFadden D, Osler T. Improved survival of patients with pseudomyxoma peritonei receiving intraperitoneal chemotherapy with cytoreductive surgery: a systematic review and meta-analysis. J Surg Res. 2013;183:246-52.